Drug Trial Radar · NCT06426485
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets
Last checked: Nov 20, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
736
Planned (sponsor's estimate)
Start
May 30, 2024
Primary completion
Feb 28, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized withdrawal, double-blind, parallel, placebo-controlled design clinical trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets to evaluate the long-term efficacy and safety in the treatment of Chinese patients with depression.
Conditions
- Major Depressive Disorder
Interventions
Toludesvenlafaxine Hydrochloride Sustained-release TabletsDrug
orally once a day
placeboDrug
orally once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to relapse.Time frame: from Baseline to week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.